Cantab Biopharmaceuticals Ltd is a drug development company focused on the development of "biosuperior" products. Based on Cambridge Science Park, Cantab is at the heart of the largest biotech cluster in Europe. Cantab is using it's extensive experience in biopharmaceutical discovery, process development and GMP manufacturing to expedite the development of biosuperiors from inception through clinical development. Previously marketed, off-patent, biologics will be enhanced by the application of appropriate cutting-edge technologies in protein expression/engineering, process/manufacturing technology, protein conjugation, formulation and drug delivery. Particular areas of drug characteristics that Cantab seek to improve upon are product presentation and stability, pharmacokinetics, pharmacodynamics, immunogenicity and drug delivery.
Leveraging the extensive knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.
Xenova publicly quoted biotechnology company focused on the development of novel drugs to treat cancer and addiction.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.